Currently, there are 42.24M common shares owned by the public and among those 41.77M shares have been available to trade.
The company’s stock has a 5-day price change of -84.63% and -85.09% over the past three months. SAVA shares are trading -80.92% year to date (YTD), with the 12-month market performance down to -79.88% lower. It has a 12-month low price of $8.79 and touched a high of $42.20 over the same period. SAVA has an average intraday trading volume of 1.77 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -83.15%, -84.14%, and -81.21% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Cassava Sciences Inc (NASDAQ: SAVA) shares accounts for 29.66% of the company’s 42.24M shares outstanding.
It has a market capitalization of $170.03M and a beta (3y monthly) value of -0.60. The earnings-per-share (ttm) stands at -$1.37. Price movements for the stock have been influenced by the stock’s volatility, which stands at 20.91% over the week and 10.40% over the month.
Analysts forecast that Cassava Sciences Inc (SAVA) will achieve an EPS of -0.36 for the current quarter, 0 for the next quarter and -0.65 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.36 while analysts give the company a high EPS estimate of -0.36. Comparatively, EPS for the current quarter was -0.5 a year ago. Earnings per share for the fiscal year are expected to increase by 67.67%, and 116.67% over the next financial year.
Looking at the support for the SAVA, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on October 08, 2024, with the firm’s price target at $116. B. Riley Securities was of a view on November 16, 2022 that the stock is Neutral, while Cantor Fitzgerald gave the stock Neutral rating on July 15, 2021, issuing a price target of $100. Maxim Group on their part issued Buy rating on July 07, 2021.
